What is hyperemesis gravidarum?

Hyperemesis gravidarum (HG) is severe nausea and vomiting in pregnancy. It is much more than common morning sickness: it involves persistent severe vomiting that interferes with eating and drinking, weight loss (often more than 5 percent of pre-pregnancy weight), dehydration, electrolyte disturbance, and substantial impact on daily functioning. HG affects roughly 1 to 3 percent of pregnancies and is one of the most common reasons for hospitalisation during pregnancy.

Why it is more than morning sickness. Many people experience some nausea and vomiting in early pregnancy. For most, symptoms are bothersome but manageable and resolve by the second trimester. Hyperemesis gravidarum is at the severe end of the spectrum: persistent, debilitating, often associated with weight loss and dehydration severe enough to require IV fluid replacement, sometimes lasting most or all of the pregnancy.

Why it has been undertreated. The historical assumption that nausea and vomiting in pregnancy is an expected and time-limited inconvenience has led to underrecognition of the severe end of the spectrum. Many women with HG have felt that their symptoms were dismissed; many have lost weight, lost work, and experienced substantial mental health impact while being told to wait it out. Modern care emphasises recognising HG as a serious condition deserving structured care.

What causes it. The biology has been incompletely understood. Recent research has identified GDF15 (growth differentiation factor 15) as a major contributor: women with HG have higher GDF15 levels in pregnancy and altered sensitivity to GDF15. Genetic variations in GDF15 and its receptor are associated with HG risk. GDF15-targeted therapy programs are entering early clinical trials with the proposition of treating the underlying mechanism.

The therapy options.

For mild to moderate nausea and vomiting: lifestyle measures (small frequent meals, ginger, avoiding triggers), pyridoxine (vitamin B6), and pyridoxine plus doxylamine combination as first-line pharmacotherapy.

For moderate persistent symptoms: ondansetron is widely used and generally considered safe in pregnancy based on accumulated evidence; metoclopramide and other antiemetics are alternatives.

For hyperemesis gravidarum: structured care with multiple components. IV fluid replacement (sometimes through outpatient infusion pathways that reduce hospitalisation), combination antiemetic therapy, careful electrolyte monitoring and replacement, thiamine supplementation to prevent Wernicke encephalopathy in prolonged vomiting, corticosteroids in selected refractory cases, and (in severe cases) nasoenteric or parenteral nutrition.

Integrated care: HG often has substantial mental health impact, both from the physical symptoms and from feeling unsupported. Integrated obstetric-and-mental-health care models address both dimensions.

The emerging direction. GDF15-targeted programs may offer the first mechanism-targeted therapy for HG. Whether modulating GDF15 signalling can prevent or treat severe HG is being tested in early trials.

What to expect. With modern structured care, most women with HG can be managed through their pregnancy with substantially better quality of life than was possible with older approaches. Recognising the severity, access to appropriate hydration and antiemetic therapy, integrated mental health support, and (in severe cases) nutritional support are the components of comprehensive care. If you or someone you know is experiencing severe nausea and vomiting in pregnancy, seeking structured medical care is the right step; suffering through HG without adequate treatment is no longer the appropriate standard.